Wonder molecule mRNA, 3

«The mRNA technology still holds enormous potential», says the man who played a key role in the development of the COVID vaccine

photo of author of the article

UPenn professor Norbert Pardi has carried forward in the United States the work of future Nobel laureate Katalin Karikó since her dismissal. The scientist now plays a central role in advancing mRNA therapies, particularly vaccines.

Professor Norbert Pardi also collaborates with Swiss researchers.

Professor Norbert Pardi also collaborates with Swiss researchers.

Pic: Daniel Burke

Continuation from part 2

There is no shortage of visions for mRNA-based therapies. The technology is now being used to develop flu vaccines, cure liver diseases, treat cancer, and combat autoimmune disorders. The possibilities are almost limitless, because every human cell uses mRNA to produce proteins. Biotech companies and governments are, therefore, investing billions into exploring mRNA-based treatments.

For many years, however, the problem was that lab-produced mRNA was chemically slightly different from the body’s own mRNA, and experiments with it triggered unwanted inflammatory reactions. Then in 2005, Katalin Karikó and Drew Weissman discovered and published that by slightly modifying the chemical composition of mRNA, this problem could be largely avoided. For this groundbreaking discovery, the two were awarded the Nobel Prize in Physiology or Medicine two years ago.

Norbert Pardi as guardian of the future of mRNA vaccines and therapies

For mRNA to have any effect in the body – such as inducing immunity against coronaviruses in the case of the COVID vaccine – it must somehow be delivered into cells. That challenge is precisely the focus of Hungarian researcher Norbert Pardi. The biochemist is considered one of the world’s leading experts in this area, having helped demonstrate the most common form of mRNA delivery: lipid nanoparticles, which were also used in the BioNTech and Moderna COVID vaccines.

«Lipid nanoparticles are a simple and efficient way to deliver mRNA into cells,» Pardi explains. They usually consist of just four different types of lipid molecules. One can imagine them as tiny fat droplets that can pass through cell membrane and carry therapeutic mRNA. Compared with other delivery methods, lipid nanoparticles are seen as low-risk and easy-to-produce.

As of now, lipid nanoparticles are, therefore, regarded as perhaps the most promising technology for the development of future mRNA therapies. «We collaborate with labs around the world, including some in Switzerland,» Pardi says. His team can produce and package mRNA molecules into lipid nanoparticles and prepare them so they can be administered. In 2025, with hundreds of clinical studies already underway using mRNA-based agents against previously incurable diseases, such expertise is worth gold.

He advanced further at the university than his mentor

Researcher Norbert Pardi has followed a path strikingly similar to that of his mentor, Katalin Karikó. Both were born in the same Hungarian small town, studied in Szeged, and later moved to the U.S. – albeit decades apart. «Without Kati I would never have entered the field of mRNA technology,» Pardi says today. «She brought me to the U.S. because of my interest, after I wrote her a letter as a student. After my arrival, Kati, Drew Weissman, and myself would spend hours every day discussing science.» She was incredibly detail-oriented and bold in her thinking. «That left a mark on me.»

A collaboration with great impact: future Nobel Prize winner Katalin Karikó with Norbert Pardi in 2012.

A collaboration with great impact: future Nobel Prize winner Katalin Karikó with Norbert Pardi in 2012.

Pic: provided

When Karikó lost her job just before Christmas in 2012, because the university felt she attracted too few funders, Pardi stayed in the laboratory of Drew Weissman, and continued his work. Unlike Kati, he advanced at the prestigious University of Pennsylvania, eventually becoming a professor with his own research team. That may have been due to his winning personality – or to the fact that, as a young researcher, he published the right work at the right time, with lipid nanoparticles already seen as a technology of the future. Or simply to his productivity: Pardi has already developed 16 technologies that have been patented.

At 44, he still has big plans. Not only because he is young for a professor, but because, like Karikó, he is driven by science. Anyone who speaks with him feels the energy that explains his long days in the lab. «I see the greatest potential for mRNA technology initially in vaccines against infectious diseases,» Pardi explains. Because mRNA can easily be adapted to target any virus, most bacteria, and even other infectious agents, its potential is immense. “Once that works well, we’ll be able to use mRNA against cancer and for many other non-vaccine applications such as protein replacement or genome editing.

Continuing what Karikó began

But safety must always remain front and center. Pardi believes it’s important to speak openly about any potential safety concerns of vaccine skeptics. So far, however, he says he has seen no convincing argument against mRNA therapies. His team monitors new findings on this front very closely. In his Philadelphia-based lab he continually conducts experiments in mice, rats, and monkeys and test not only the efficacy but also the safety of new therapies.

Article series

Miracle Molecule mRNA – Katalin Karikó’s Legacy

No other method holds as much potential to revolutionize medicine as mRNA technology. The mRNA research, significantly shaped by the Hungarian-American biochemist Katalin Karikó, has doctors dreaming of curing infectious diseases, genetic disorders, and cancer within the coming years. In this series, we highlight projects by leading researchers who, building on Karikó’s work, are introducing mRNA technology into various fields of medicine.

«It’s important to emphasize that mRNA therapies are elegant precisely because they don’t alter the genome,» he says. mRNA cannot be incorporated into the genome. Pardi, therefore, believes the first groundbreaking therapies will soon find their way into hospitals.

The professor is doing his part in Philadelphia. In his university lab, he is carrying forward the work that Katalin Karikó began in the 1980s. He has not forgotten his now-famous mentors: he remains in contact with both Weissman and Karikó, discussing new studies whenever fresh insights emerge from the world of mRNA research.

This is a longstanding pattern. When Katalin Karikó was dismissed from the University of Pennsylvania 13 years ago, she continued to keep in touch with many former colleagues. Even after moving to Germany to work at BioNTech, where she helped end the COVID pandemic with her vaccine, she encountered new scientists who would go on to shape her in unexpected ways…

Part 4 of the series can be found here .

Note

* This article series has been nominated for the Prix Média Newcomer 2025 and was supported by the Swiss Academy of Sciences.

Mehr zum Thema
Wonder molecule mRNA, 1

How a Butcher's Daughter Saved Millions of Lives — and Is Now Helping to Cure Countless Diseases

09.09.2025
Wonder molecule mRNA, 2

The World's Most Famous Neurosurgeon in Conversation: «Empathy Is Important, But Not The Essential Quality For a Doctor»

09.09.2025
David Langer also teaches young doctors to become neurosurgeons.
Wonder molecule mRNA, 3

«The mRNA technology still holds enormous potential», says the man who played a key role in the development of the COVID vaccine

09.09.2025
Professor Norbert Pardi also collaborates with Swiss researchers.
Wonder molecule mRNA, 4

A Nobel Prize Winner at BioNTech: Why Katalin Karikó Remembers Two Collegues So Fondly

09.09.2025
The mRNA pioneer with BioNTech researcher Jason Keller at a conference.
Wonder molecule mRNA, 5

How Swiss Funding Is Helping Top Scientist Katalin Karikó Boost mRNA Research in Europe

09.09.2025
Professor Attila Gácser is working to turn Hungary’s University of Szeged into a leading center for mRNA research.

Für Sie empfohlen

Melden Sie sich an und erhalten Sie hier Ihre individuellen Leseempfehlungen.

Aktuelle Nachrichten